InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that data from the Phase 3 study of vilobelimab ...

Lice checks were a dreaded part of my childhood — I remember anxiously waiting for the nurse to call my name for a checkup, hoping a call home wouldn’t follow (sometimes, I wasn’t so lucky). Head lice ...

Everyday Health independently vets all recommended products. If you purchase a featured product, we may be compensated. Learn why you can trust us. Everyday Health independently vets all recommended ...

A systematic review of 63 cases found that pyoderma gangrenosum (PG) during pregnancy or postpartum was often misdiagnosed, delaying treatment and leading to inappropriate interventions. Researchers ...

InflaRx N.V. (NASDAQ:IFRX) on Wednesday announced that the Independent Data Monitoring Committee (IDMC) conducting the unblinded interim analysis for the Phase 3 trial for vilobelimab in pyoderma ...

ABSTRACT: Hidradenitis suppurativa (HS) is a refractory and recurrent chronic inflammatory skin disease characterized by nodules, abscesses, sinus tracts, and scarring. The etiology of HS remains ...

InflaRx N.V. has announced the presentation of data on vilobelimab, its anti-inflammatory therapeutic targeting the complement system, at the 2025 American Academy of Dermatology Annual Meeting. The ...

Uncover the truth about alternative medicine in cancer care. Learn how acupuncture, herbs, and supplements can complement treatment—and what to avoid. A cancer diagnosis is a challenging journey and ...

Pyoderma Gangrenosum Market Outlook 2025-2035: The 7 major pyoderma gangrenosum market reached a value of USD 130.9 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 191.8 ...

In a lecture at VMX, Jason B. Pieper, DVM, MS, DACVD, outlined the next steps in the treatment of pyoderma in dogs when the infection is non-responsive to topical therapy Recommendations for systemic ...